LMI070
Total Payments
$13,768
Transactions
2
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $13,400 | 1 | 0 |
| 2017 | $367.50 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,768 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL MULTI PART FIRST IN HUMAN STUDY OF ORAL LMI070 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY | Novartis Pharmaceuticals Corporation | $13,400 | 0 |
| AN OPEN LABEL MULTI PART FIRST IN HUMAN STUDY OF ORAL LMI070 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY | NOVARTIS PHARMACEUTICALS CORPORATION | $367.50 | 1 |
Top Doctors Receiving Payments for LMI070
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $13,400 | 1 |
| , MD | Diagnostic Radiology | Rochester, NY | $367.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $13,768
- Total Doctors 1
- Transactions 2
About LMI070
LMI070 is a drug associated with $13,768 in payments to 1 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is NOVARTIS PHARMACEUTICALS CORPORATION.
Payment data is available from 2017 to 2019. In 2019, $13,400 was paid across 1 transactions to 0 doctors.
The most common payment nature for LMI070 is "Unspecified" ($13,768, 100.0% of total).
LMI070 is associated with 2 research studies, including "AN OPEN LABEL MULTI PART FIRST IN HUMAN STUDY OF ORAL LMI070 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY" ($13,400).